Xellia is a specialty pharmaceutical group focused on the development, manufacturing and global commercialisation of anti-infective therapies. During our ownership, Xellia transformed from a supplier of niche active pharmaceutical ingredients to a fully integrated speciality pharmaceutical company.
During our investment period, Xellia invested more than $100 million in research and development (‘R&D’) and capacity expansion across its global manufacturing network, including a new ﬁll-ﬁnish plant in Copenhagen.
“3i’s investment and continued support, expertise and commitment has enabled Xellia to successfully grow and transition the business to become leaders in the supply of key anti-infective products.” Carl-Åke Carlsson, Chief Executive and President, Xellia
This transaction involved a recommendation of 3i Investments plc, advised by 3i Sweden.